Beta Bionics Predicts $30M Q4 Revenue; Analysts See 106.7% Upside
Beta Bionics Inc forecasts Q4 2025 revenue of $30 million and a loss of $0.42 per share, after Q3 revenue of $30 million beat estimates by 13.7% and EPS beat by 24.3%, driving a 10.3% stock jump. Eleven analysts’ average one-year price target of $28.82 implies 106.7% upside.
1. Upcoming Q4 2025 Estimates
Beta Bionics forecasts Q4 2025 revenue of $30 million and an EPS loss of $0.42, aligning with consensus estimates. Full-year 2025 revenue is projected at $100 million with a per-share loss of $1.94.
2. Q3 Performance and Stock Reaction
In Q3 2025, Beta Bionics reported $30 million revenue, beating estimates by 13.7%, and an EPS loss of $0.33, exceeding forecasts by 24.3%. Shares rose 10.3% in one trading day following the release.
3. Analyst Price Targets and Recommendations
Eleven analysts set a one-year price target average of $28.82, with a high of $40 and low of $17, implying 106.7% upside. The consensus brokerage rating of 1.9 reflects an Outperform stance.